Methods of determining patient response by measurement of HER-3 and P95
First Claim
Patent Images
1. A method for quantifying Her-3 and p95 levels in a sample from a subject that has a cancer, comprising:
- (a) obtaining a sample from the subject'"'"'s cancer;
(b) measuring the amount of Her-3 and p95 in the sample using a Her-3 antibody and a p95 antibody that specifically binds to a p95 protein having a first amino acid corresponding to methionine 611 of human Her-2 protein; and
(c) quantifying the amount of Her-3 and p95 in the subject'"'"'s sample,wherein the Her 3 antibody is at least one of;
a monoclonal antibody comprising (a) a light chain variable region comprising CDR1, CDR2 and CDR3 having sequences as set forth in SEQ ID NOs;
13, 14 and 15, respectively, and (b) a heavy chain variable region comprising CDR1, CDR2 and CDR3 having sequences as set forth in SEQ ID NOs;
16, 17 and 18, respectively;
a monoclonal antibody comprising (a) a light chain variable region comprising CDR1, CDR2 and CDR3 having sequences as set forth in SEQ ID NOs;
19, 20 and 21, respectively, and (b) a heavy chain variable region comprising CDR1, CDR2 and CDR3 having sequences as set forth in SEQ ID NOs;
22, 23 and 24, respectively,an antibody comprising amino acid sequences set forth in SEQ ID NOs;
9 and 11 for the light and heavy chains, respectively, oran antibody comprising amino acid sequences set forth in SEQ ID NOs;
10 and 12 for the light and heavy chains, respectively.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex and the presence and/or amount of p95 in a sample. The invention also provides antibodies specific for Her-3.
-
Citations
14 Claims
-
1. A method for quantifying Her-3 and p95 levels in a sample from a subject that has a cancer, comprising:
-
(a) obtaining a sample from the subject'"'"'s cancer; (b) measuring the amount of Her-3 and p95 in the sample using a Her-3 antibody and a p95 antibody that specifically binds to a p95 protein having a first amino acid corresponding to methionine 611 of human Her-2 protein; and (c) quantifying the amount of Her-3 and p95 in the subject'"'"'s sample, wherein the Her 3 antibody is at least one of; a monoclonal antibody comprising (a) a light chain variable region comprising CDR1, CDR2 and CDR3 having sequences as set forth in SEQ ID NOs;
13, 14 and 15, respectively, and (b) a heavy chain variable region comprising CDR1, CDR2 and CDR3 having sequences as set forth in SEQ ID NOs;
16, 17 and 18, respectively;a monoclonal antibody comprising (a) a light chain variable region comprising CDR1, CDR2 and CDR3 having sequences as set forth in SEQ ID NOs;
19, 20 and 21, respectively, and (b) a heavy chain variable region comprising CDR1, CDR2 and CDR3 having sequences as set forth in SEQ ID NOs;
22, 23 and 24, respectively,an antibody comprising amino acid sequences set forth in SEQ ID NOs;
9 and 11 for the light and heavy chains, respectively, oran antibody comprising amino acid sequences set forth in SEQ ID NOs;
10 and 12 for the light and heavy chains, respectively. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
Specification